Trinity Biotech projects an annualized run rate of $20 million in EBITDASO and $75 million in revenues by Q2 2025, with a 20% sales increase and a $6.5 million EBITDA turnaround anticipated in 2025.

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market.

DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management ...

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its position in Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% in the ...

Looking for the most shorted stocks?

Trinity Biotech plc (NASDAQ:TRIB), a leading developer of diagnostic products for the healthcare industry trading near its 52-week low of $0.56, today announced a significant change in its executive ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...